<DOC>
	<DOC>NCT02396706</DOC>
	<brief_summary>Randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of a liquid containing ivy leaves dry extract vs. placebo in the treatment of acute cough</brief_summary>
	<brief_title>RCT to Evaluate the Efficacy and Safety of Ivy Leaves Cough Liquid vs. Placebo in the Treatment of Acute Cough</brief_title>
	<detailed_description />
	<mesh_term>Cough</mesh_term>
	<criteria>1. Acute cough with symptoms lasting 23 days prior to treatment 2. Men or women of any ethnic origin 3. Age 18 to 75 years 4. Subjects who are able to understand and are willing to comply to trial instructions 5. Having given written informed consent 6. Satisfactory health except for the cough as determined by the investigator based on medical history and physical examination 7. CS score of at least 50 mm on a 100 mm VAS at V1 8. Acute BSS of at least 10 points at V1 9. VCD score of at least 2 points at V1 1. Allergic bronchial asthma, bronchial hyperreactivity, chronic bronchitis, other chronic or inherited lung disease 2. History of hypersensitivity to any excipient of the applied drugs 3. History of drug hypersensitivity, asthma, urticaria, or other severe allergic diathesis as well as current hay fever 4. History of chronic gastritis or peptic ulcers 5. Any gastrointestinal complaints within 7 days before V1 6. Participation in a clinical trial within 30 days prior to the treatment phase of this study or concomitantly 7. Treatment with corticoids, beta2 agonists (e.g. salbutamol, fenoterol), expectorants, theophylline, antitussives, anaesthetics, acetylsalicylic acid (e.g. aspirin) or other nonsteroidal antiinflammatory drugs, leukotriene inhibitors, angiotensinconverting enzyme (ACE) inhibitors, antiviral drugs or antibiotics, antihistamines, immunosuppressants, isoprenaline, atropine, sodium cromoglycate or homeopathic drugs against common cold within 7 days before V1 8. Drug or alcohol abuse in the opinion of the investigator 9. Pregnant or nursing (lactating) women 10. Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) who are not using an acceptable method of contraception. 11. Subjects with significant diseases, defined as a disease which, in the opinion of the investigator, may either put the subject at risk because of participation in the trial or a disease which may influence the results of the trial or the subject's ability to participate in the trial; includes subjects with a history of gastrointestinal bleeding, significant cardiovascular, liver or renal disease. 12. Subjects directly or indirectly involved in the execution of this protocol, including employees of the CRO and persons related to them.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>